CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

科学研究

Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Prevalence, Presentation and Treatment of 'Balloon Undilatable' Chronic Total Occlusions: Insights from a Multicenter US Registry Shock Team Approach in Refractory Cardiogenic Shock Requiring Short-Term Mechanical Circulatory Support: A Proof of Concept Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes: From the BIONICS and NIREUS Trials Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure

Sort by hits |<<... 45 46 47 48 49 50 51 ...>>|

JOURNAL： Article Link

AsiaIntervention正式被PubMed Central收录

admin

AsiaIntervention is the official journal of the Asian Pacific Society of Interventional Cardiology (APSIC) and the Interventional Cardiology Foundation of India (ICFI). Driven by a group of recognised experts worldwide, AsiaIntervention is an international, English language, peer-reviewed journal whose aim is to create a forum of high-quality research and educational articles in the field of percutaneous and surgical cardiovascular interventions with particular emphasis on scientific contributions from the Asia-Pacific region.

亚太地区人口占世界人口的60%以上，在经济高速发展的同时，介入心脏病学发展速度也领先全球。为进一步满足亚太地区医学界科研成果交流的愿景，着力突出亚太地区学者的科学贡献，在亚太介入心脏病学会（the Asian Pacific Society of Interventional Cardiology, APSIC）与印度介入心脏病基金会（ICFI）的共同努力下，AsiaIntervention这一接收全世界投稿、同行评议、英文版心血管病介入杂志应运而生，其创刊愿景是构建一个由具全球高学术影响力的心血管专家推动的服务于经皮和外科心血管干预领域学术交流和教育的高水平平台。AsiaIntervention编委会成员由来自亚太和欧洲地区知名编辑组成，保障了杂志的专业多元化和独立性。五位总编由来自领域内有声望的副主编和责编协助，我院陈绍良教授荣任副主编。

AsiaIntervention接收文章类型多元，涉及原创研究、临床研究、名家综述、专题报道、评论文章和心脏病学影像等多种形式。发表前由编辑委员会和选中的介入心脏病学的专家评审，同行评审过程为单盲。杂志每年出版两期，包括印刷版和电子版。

自2015年创刊后，AsiaIntervention于近期申请了Science Citation Index® (ISI)、SciVerse Scopus、MEDLINE®/PubMed®索引收录，并于2021年12月17日正式获PubMed Central收录。

点击阅读原文可直接访问AsiaIntervention官方网站在线投稿，陈绍良教授诚邀各位心血管临床和科研工作者积极投稿。

科研文章

荐读文献

AsiaIntervention正式被PubMed Central收录

科研文章

荐读文献

​AsiaIntervention正式被PubMed Central收录

AsiaIntervention正式被PubMed Central收录